(Reuters) -The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, resigned on Sunday amid serious concerns about his personal conduct, a Department of Health and Human Services spokesperson told Reuters on Monday.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration.

() -​Rhythm Pharmaceuticals ‌said on Friday ‌the U. Food and ⁠Drug ‌Administration has extended the ‍review period for expanded approval ​of its ‌drug, Imcivree, as a treatment for ⁠a rare ​form ​of obesity.

The top drug regulator at the Food and Drug Administration (FDA) resigned Sunday, according to officials, after being accused of using his position of authority to publicly denigrate a treatment tied to a former business associate.

George Tidmarsh left the agency amid accusations of misusing his authority and after clashing with another top official.

The dramatic shift in oversight comes at a time when the U.S. has never been more reliant on foreign food, which accounts for the vast majority of the nation’s seafood and more than half its fresh fruit.

The FDA has sent warning letters to 18 websites selling counterfeit or unapproved versions of Botox and similar injectable drugs commonly used to smooth wrinkles.

New professional guidance to the nation's pediatricians advises against using a drug in children with autism that many families are clamoring for after it was hyped by federal officials.